Next Article in Journal
The Gap Junction Inhibitor Octanol Decreases Proliferation and Increases Glial Differentiation of Postnatal Neural Progenitor Cells
Previous Article in Journal
Arrestins: A Small Family of Multi-Functional Proteins
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy

1
Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China
2
Key Laboratory of Reproductive and Developmental Biology, Dalian Medical University, Dalian 116044, China
3
Core Laboratory of Glycobiology and Glycoengineering, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2024, 25(11), 6286; https://doi.org/10.3390/ijms25116286
Submission received: 27 March 2024 / Revised: 27 May 2024 / Accepted: 28 May 2024 / Published: 6 June 2024
(This article belongs to the Section Molecular Endocrinology and Metabolism)

Abstract

Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.
Keywords: diabetic retinopathy; O-GlcNAc modification; photoreceptor; apoptosis; AMPK diabetic retinopathy; O-GlcNAc modification; photoreceptor; apoptosis; AMPK

Share and Cite

MDPI and ACS Style

Dong, W.; Imdad, L.; Xu, S.; Wang, Y.; Liu, C.; Song, S.; Li, Z.; Kong, Y.; Kong, L.; Ren, X. O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy. Int. J. Mol. Sci. 2024, 25, 6286. https://doi.org/10.3390/ijms25116286

AMA Style

Dong W, Imdad L, Xu S, Wang Y, Liu C, Song S, Li Z, Kong Y, Kong L, Ren X. O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy. International Journal of Molecular Sciences. 2024; 25(11):6286. https://doi.org/10.3390/ijms25116286

Chicago/Turabian Style

Dong, Wenkang, Laraib Imdad, Shengnan Xu, Yinli Wang, Chengzhi Liu, Shiyu Song, Zechuan Li, Ying Kong, Li Kong, and Xiang Ren. 2024. "O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy" International Journal of Molecular Sciences 25, no. 11: 6286. https://doi.org/10.3390/ijms25116286

APA Style

Dong, W., Imdad, L., Xu, S., Wang, Y., Liu, C., Song, S., Li, Z., Kong, Y., Kong, L., & Ren, X. (2024). O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy. International Journal of Molecular Sciences, 25(11), 6286. https://doi.org/10.3390/ijms25116286

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop